Kexing Biopharm Co., Ltd. (SHA:688136)
China · Delayed Price · Currency is CNY 26.02
-0.48 (-1.81%)
May 12, 2026, 3:00 PM CST
Kexing Biopharm Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 1,461 | 1,534 | 1,403 | 1,256 | 1,300 | 1,285 |
Other Revenue | - | - | 3.52 | 3.19 | 15.84 | 0.45 |
| 1,461 | 1,534 | 1,407 | 1,259 | 1,316 | 1,285 | |
Revenue Growth (YoY) | 4.37% | 9.03% | 11.75% | -4.32% | 2.39% | 5.32% |
Cost of Revenue | 564.39 | 561.97 | 444.2 | 370.31 | 324.66 | 265.3 |
Gross Profit | 896.6 | 972.05 | 962.73 | 888.72 | 991.21 | 1,020 |
Selling, General & Admin | 636.47 | 668.04 | 682.73 | 776.11 | 913.6 | 846.08 |
Research & Development | 196.41 | 199.55 | 168.05 | 344.8 | 193.3 | 122.95 |
Other Operating Expenses | 6.78 | 6.86 | 12.03 | 11.46 | 9.69 | 9.78 |
Operating Expenses | 839.66 | 874.45 | 864.21 | 1,129 | 1,117 | 977.66 |
Operating Income | 56.94 | 97.61 | 98.52 | -240.71 | -125.34 | 42.21 |
Interest Expense | - | - | -44.85 | -40.72 | -28.7 | -8.03 |
Interest & Investment Income | 28.25 | 29.82 | 12.95 | 13.17 | 9.49 | 18.25 |
Currency Exchange Gain (Loss) | - | - | 0.74 | 3.29 | 6.95 | -1.53 |
Other Non Operating Income (Expenses) | -48.78 | -39.63 | -0.58 | -0.76 | -1.78 | -3.88 |
EBT Excluding Unusual Items | 36.41 | 87.8 | 66.78 | -265.72 | -139.39 | 47.03 |
Gain (Loss) on Sale of Investments | 76.57 | 79.29 | -29.19 | 0.24 | -5.35 | 47.46 |
Gain (Loss) on Sale of Assets | 0.94 | 0.95 | 0.08 | 0.28 | 1.05 | -2.74 |
Asset Writedown | -5.84 | -2.34 | -0.17 | -1.6 | - | - |
Other Unusual Items | - | - | 19.41 | 6.73 | 4.63 | 3.88 |
Pretax Income | 108.08 | 165.7 | 56.9 | -260.07 | -139.06 | 95.63 |
Income Tax Expense | -1.26 | 12.96 | 29.85 | -64.58 | -46.24 | -0.84 |
Earnings From Continuing Operations | 109.34 | 152.74 | 27.05 | -195.49 | -92.82 | 96.46 |
Minority Interest in Earnings | 2.71 | 2.82 | 4.43 | 5.2 | 2.53 | - |
Net Income | 112.05 | 155.57 | 31.48 | -190.29 | -90.3 | 96.46 |
Net Income to Common | 112.05 | 155.57 | 31.48 | -190.29 | -90.3 | 96.46 |
Net Income Growth | 150.93% | 394.17% | - | - | - | -30.67% |
Shares Outstanding (Basic) | 198 | 197 | 197 | 198 | 201 | 197 |
Shares Outstanding (Diluted) | 198 | 197 | 197 | 198 | 201 | 197 |
Shares Change (YoY) | 0.67% | 0.08% | -0.74% | -1.21% | 1.93% | 31.59% |
EPS (Basic) | 0.57 | 0.79 | 0.16 | -0.96 | -0.45 | 0.49 |
EPS (Diluted) | 0.57 | 0.79 | 0.16 | -0.96 | -0.45 | 0.49 |
EPS Growth | 149.27% | 393.75% | - | - | - | -47.31% |
Free Cash Flow | -21.04 | 2.4 | 12.68 | -278.34 | -485.06 | -277.97 |
Free Cash Flow Per Share | -0.11 | 0.01 | 0.06 | -1.40 | -2.42 | -1.41 |
Dividend Per Share | - | - | 0.080 | - | - | 0.100 |
Dividend Growth | - | - | - | - | - | 25.00% |
Gross Margin | 61.37% | 63.37% | 68.43% | 70.59% | 75.33% | 79.36% |
Operating Margin | 3.90% | 6.36% | 7.00% | -19.12% | -9.53% | 3.28% |
Profit Margin | 7.67% | 10.14% | 2.24% | -15.11% | -6.86% | 7.51% |
Free Cash Flow Margin | -1.44% | 0.16% | 0.90% | -22.11% | -36.86% | -21.63% |
EBITDA | 157.88 | 195.58 | 184.6 | -167.64 | -70.32 | 77.41 |
EBITDA Margin | 10.81% | 12.75% | 13.12% | -13.31% | -5.34% | 6.02% |
D&A For EBITDA | 100.94 | 97.97 | 86.08 | 73.07 | 55.03 | 35.2 |
EBIT | 56.94 | 97.61 | 98.52 | -240.71 | -125.34 | 42.21 |
EBIT Margin | 3.90% | 6.36% | 7.00% | -19.12% | -9.53% | 3.28% |
Effective Tax Rate | - | 7.82% | 52.46% | - | - | - |
Revenue as Reported | - | - | 1,407 | 1,259 | 1,316 | 1,285 |
Advertising Expenses | - | - | - | - | - | 5.68 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.